Here are the 10-Q quarterly reports from Mountain Crest Acq V RTS (MCAGR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MCAGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCAGR filings page.
Mountain Crest Acquisition Corp. V is a SPAC that has not yet completed a Business Combination and remains in pre-revenue status. For the quarter ended June 30, 2026, it reported net income of $5,178, versus a net loss of $110,574 a year earlier, mainly due to a $100,000 gain on extinguishment of liabilities and $7,506 of interest on its Trust Account. For the first six months of 2026, it recorded a net loss of $108,797, an improvement from a loss of $291,952 for the same period in 2025.
Total assets were $889,852 at June 30, 2026, including $855,537 in the Trust Account and $18,299 of cash outside the trust. Liabilities totaled $3,847,545, driven by a $2,070,000 deferred underwriting fee and $1,550,000 of related-party promissory notes, resulting in a stockholders’ deficit of $3,800,349 and 72,123 shares of common stock classified as redeemable at an aggregate $842,656. The company’s securities were delisted from Nasdaq in November 2024 and now trade on the OTC Pink Market.
Management discloses that it has until November 16, 2026 to consummate a Business Combination, subject to periodic sponsor-funded extensions, and states that mandatory liquidation and dissolution would follow if no deal is completed. Limited working capital and reliance on sponsor loans lead to a conclusion that there is substantial doubt about the company’s ability to continue as a going concern, even as it continues pursuing a previously signed Business Combination Agreement with CUBEBIO Co., Ltd.
Mountain Crest Acquisition Corp. V, a SPAC, reported a Q1 2026 net loss of $113,975, driven mainly by general and administrative expenses of $120,046. Interest income on the Trust Account was modest at $7,392, reflecting its small remaining balance.
Total assets were $986,588 as of March 31, 2026, including $848,031 in the Trust Account and $97,101 of cash held outside the trust. Current liabilities were $1,879,459, largely related-party promissory notes, plus a $2,070,000 deferred underwriting fee, leaving a stockholders’ deficit of $3,802,061. The company has experienced extensive redemptions, with only 72,123 redeemable Public Shares outstanding and 2,873,023 total common shares issued and outstanding as of May 15, 2026.
Management discloses substantial doubt about the company’s ability to continue as a going concern because it must complete a Business Combination by November 16, 2026 or liquidate. Its securities were delisted from Nasdaq in November 2024 and now trade on the OTC Pink Market. The company has a Business Combination Agreement with CUBEBIO Co., Ltd. and is funding ongoing costs through a series of sponsor promissory notes.